血浆Periostin蛋白和NT-proBNP联合血清Hcy检测在心力衰竭患者临床疗效及预后评估中的应用价值

Application of plasma Periostin protein, NT-proBNP combined with serum Hcy in the treatment and prognosis evaluation of patients with heart failure

目的 探讨血浆骨膜(Periostin)蛋白、N氨基末端脑钠肽前体(NT-proBNP)联合血清同型半胱氨酸(Hcy)检测在评估心力衰竭患者临床疗效及预后中的价值。方法 选取2018年1月至2019年6月于本院心内科确诊的80例慢性心力衰竭(CHF)患者作为研究组,另选取本院同期经体检确认健康的80名志愿者作为对照组。检测并比较所有研究对象的血浆Periostin蛋白、NT-proBNP、血清Hcy水平和左室射血分数(LVEF)。结果 治疗前后,研究组血浆Periostin蛋白、NT-proBNP和血清Hcy水平均高于对照组,LVEF水平低于对照组(P<0.05);治疗后,研究组血浆Periostin蛋白、NT-proBNP及血清Hcy水平均低于治疗前,LVEF水平高于治疗前,差异有统计学意义(P<0.05)。随访6、12个月后,研究组发生心脏不良事件患者的血浆Periostin蛋白、NT-proBNP、血清Hcy水平均高于病情稳定患者,且心脏不良事件中死亡患者上述指标均高于再入院患者,差异有统计学意义(P<0.05)。结论 血浆Periostin蛋白、NT-proBNP及血清Hcy水平联合检测能有效评估心力衰竭患者治疗效果,有助于预测远期预后情况。

Objective To investigate the value of plasma Periostin protein, N-terminal pro-brain natriuretic peptide(NT-proBNP) combined with serum homocysteine(Hcy) in evaluating the clinical efficacy and prognosis of patients with heart failure. Methods 80 patients with chronic heart failure(CHF) diagnosed in the Department of Cardiology of our hospital from January 2018 to June 2019 were selected as the study group,and 80 healthy volunteers confirmed by physical examination in the same period were selected as the control group. Plasma Periostin protein, NTproBNP, serum Hcy level and left ventricular ejection fraction(LVEF) were measured and compared. Results Before and after treatment, the levels of plasma Periostin protein, NT-proBNP and serum Hcy in the study group were higher than those in the control group, while the level of LVEF was lower than that in the control group(P<0.05);After treatment, the levels of plasma Periostin protein, NT-proBNP and serum Hcy in the study group were lower than those before treatment, and the level of LVEF was higher than that before treatment(P<0.05). After 6 and 12 months of follow-up, the levels of plasma Periostin protein, NT-proBNP and serum Hcy in patients with adverse cardiac events in the study group were higher than those in patients with stable conditions, and the above indexes in patients who died in adverse cardiac events were higher than those in readmission patients, the difference was statistically significant(P<0.05). Conclusion The combined detection of plasma Periostin protein, NT-proBNP and serum Hcy can effectively evaluate the therapeutic effect of patients with heart failure and help to predict the long-term prognosis.